<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>N‚ÄëMethyl‚ÄëCyclazodone (NMC) ‚Ä¢ Pharmacological and Toxicological Assessment</title>
  <meta name="color-scheme" content="dark light">

  <style>
    :root {
      /* Base dark theme */
      --bg-0: #0f1115;
      --bg-1: #13161c;
      --bg-2: #1a1f27;
      --bg-card: #171a21;
      --elev-1: 0 6px 20px rgba(0,0,0,0.35);

      /* Text */
      --txt-0: #e9edf1;
      --txt-1: #c9d1d9;
      --txt-2: #9aa4b2;
      --muted: #7f8a99;

      /* Accent palette (accessible on dark) */
      --accent: #66d9ef;      /* cyan for links/accents */
      --accent-2: #a78bfa;    /* soft purple for headings */
      --accent-3: #f59e0b;    /* amber for highlights */
      --accent-4: #34d399;    /* green for success tags */
      --accent-5: #f43f5e;    /* pink/red for warnings */

      /* Gradients and borders */
      --grad-1: linear-gradient(135deg, rgba(102,217,239,0.18), rgba(167,139,250,0.18));
      --grad-2: linear-gradient(135deg, rgba(52,211,153,0.14), rgba(245,158,11,0.14));
      --bd-strong: #2a3240;
      --bd-soft: #222834;

      /* Code/selection */
      --code-bg: #10141b;
      --sel: rgba(102,217,239,0.25);
      --focus: 0 0 0 3px rgba(102,217,239,0.35), 0 0 0 1px rgba(102,217,239,0.5);
      --ring: 0 0 0 1px var(--accent);

      /* Typography */
      --font-sans: ui-sans-serif, system-ui, -apple-system, Segoe UI, Roboto, Inter, Helvetica, Arial, "Apple Color Emoji", "Segoe UI Emoji";
      --font-mono: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace;
    }

    @media (prefers-color-scheme: light) {
      :root {
        --bg-0: #f7f8fa;
        --bg-1: #ffffff;
        --bg-2: #f0f2f6;
        --bg-card: #ffffff;
        --txt-0: #0f1720;
        --txt-1: #1f2937;
        --txt-2: #495469;
        --muted: #647087;
        --bd-strong: #d7dde8;
        --bd-soft: #e6ebf3;
        --code-bg: #f3f6fb;
        --sel: rgba(167,139,250,0.25);
        --elev-1: 0 10px 25px rgba(16,24,40,0.08);
      }
    }

    * { box-sizing: border-box; }
    html, body {
      margin: 0;
      padding: 0;
      background: radial-gradient(1200px 800px at 15% -10%, rgba(102,217,239,0.08), transparent),
                  radial-gradient(1000px 700px at 95% 10%, rgba(167,139,250,0.08), transparent),
                  var(--bg-0);
      color: var(--txt-1);
      font-family: var(--font-sans);
      line-height: 1.6;
      -webkit-font-smoothing: antialiased;
      -moz-osx-font-smoothing: grayscale;
    }

    ::selection { background: var(--sel); }

    a {
      color: var(--accent);
      text-decoration: none;
    }
    a:hover { text-decoration: underline; }

    .container {
      max-width: 900px;
      margin: 0 auto;
      padding: 88px 20px 48px;
    }

    /* Header */
    .site-header {
      position: sticky;
      top: 0;
      z-index: 50;
      backdrop-filter: saturate(140%) blur(8px);
      background: linear-gradient(to bottom, rgba(15,17,21,0.9), rgba(15,17,21,0.6));
      border-bottom: 1px solid var(--bd-soft);
    }
    .nav {
      max-width: 900px;
      margin: 0 auto;
      padding: 14px 20px;
      display: flex;
      align-items: center;
      gap: 12px;
    }
    .dot {
      width: 10px; height: 10px; border-radius: 50%;
      background: conic-gradient(from 180deg, var(--accent), var(--accent-2), var(--accent-3), var(--accent));
      box-shadow: 0 0 12px rgba(102,217,239,0.5);
    }
    .brand {
      font-weight: 700;
      letter-spacing: 0.2px;
      color: var(--txt-0);
    }
    .tag {
      margin-left: auto;
      font-size: 12px;
      color: var(--txt-2);
      background: rgba(167,139,250,0.12);
      border: 1px solid rgba(167,139,250,0.35);
      padding: 4px 10px;
      border-radius: 999px;
    }

    /* Title block */
    h1 {
      margin: 0 0 10px;
      font-size: 28px;
      font-weight: 800;
      letter-spacing: 0.2px;
      color: var(--txt-0);
      background: linear-gradient(180deg, var(--txt-0), #cfd6dd 60%, #9aa4b2);
      -webkit-background-clip: text;
      background-clip: text;
      -webkit-text-fill-color: transparent;
    }
    .meta {
      color: var(--muted);
      font-size: 14px;
    }

    /* Cards/sections */
    .notice {
      background: linear-gradient(180deg, rgba(244,63,94,0.12), rgba(244,63,94,0.06));
      border: 1px solid rgba(244,63,94,0.35);
      color: #ffd9e0;
      padding: 18px 18px;
      border-radius: 14px;
      box-shadow: var(--elev-1);
      margin: 26px 0 22px;
    }
    .notice strong { color: #ff8fa4; }

    .card {
      background: linear-gradient(180deg, rgba(26,31,39,0.9), rgba(23,26,33,0.95)), var(--bg-card);
      border: 1px solid var(--bd-soft);
      border-radius: 16px;
      box-shadow: var(--elev-1);
      padding: 18px 18px;
      margin: 18px 0;
    }
    .card.emph {
      border: 1px solid var(--bd-strong);
      background-image: var(--grad-1), linear-gradient(180deg, rgba(26,31,39,0.9), rgba(23,26,33,0.95));
    }
    .card.alt {
      background-image: var(--grad-2), linear-gradient(180deg, rgba(26,31,39,0.9), rgba(23,26,33,0.95));
    }

    h2 {
      margin: 0 0 10px;
      font-size: 20px;
      font-weight: 800;
      color: var(--accent-2);
      letter-spacing: 0.2px;
    }

    h3 {
      margin: 14px 0 6px;
      font-size: 16px;
      font-weight: 700;
      color: var(--txt-0);
    }

    p { margin: 8px 0 0; color: var(--txt-1); }

    ul {
      margin: 8px 0 0 18px;
      padding: 0;
    }
    li { margin: 6px 0; }

    .pill {
      display: inline-block;
      padding: 4px 10px;
      border-radius: 999px;
      font-size: 12px;
      border: 1px solid var(--bd-soft);
      color: var(--txt-1);
      background: rgba(102,217,239,0.08);
    }
    .pill.warn {
      background: rgba(244,63,94,0.12);
      border-color: rgba(244,63,94,0.35);
      color: #ffc0cb;
    }
    .pill.ok {
      background: rgba(52,211,153,0.12);
      border-color: rgba(52,211,153,0.35);
      color: #c9ffe7;
    }

    .kbd {
      font-family: var(--font-mono);
      background: var(--code-bg);
      border: 1px solid var(--bd-soft);
      padding: 0.2em 0.45em;
      border-radius: 6px;
      font-size: 0.9em;
      color: var(--txt-0);
    }

    /* Download / actions */
    .actions {
      display: flex;
      flex-wrap: wrap;
      gap: 12px;
      margin-top: 12px;
    }
    .btn {
      appearance: none;
      border: 1px solid var(--bd-soft);
      background: linear-gradient(180deg, #1f2530, #171b24);
      color: var(--txt-0);
      padding: 10px 14px;
      border-radius: 12px;
      font-weight: 600;
      transition: transform .05s ease, box-shadow .15s ease, background .2s ease;
      box-shadow: var(--elev-1);
      cursor: pointer;
      text-decoration: none;
      display: inline-flex;
      align-items: center;
      gap: 10px;
    }
    .btn:hover {
      transform: translateY(-1px);
      box-shadow: 0 10px 22px rgba(0,0,0,0.4);
      text-decoration: none;
    }
    .btn.primary {
      background: linear-gradient(135deg, rgba(102,217,239,0.2), rgba(167,139,250,0.2));
      border-color: rgba(102,217,239,0.5);
    }
    .btn.warn {
      background: linear-gradient(135deg, rgba(244,63,94,0.22), rgba(245,158,11,0.22));
      border-color: rgba(244,63,94,0.5);
    }

    /* Footer meta */
    .footer {
      margin-top: 18px;
      color: var(--muted);
      font-size: 13px;
      display: grid;
      grid-template-columns: 1fr;
      gap: 8px;
    }
    .meta-grid {
      display: grid;
      grid-template-columns: 1fr 1fr;
      gap: 8px 16px;
    }
    @media (max-width: 640px) {
      .meta-grid { grid-template-columns: 1fr; }
      .container { padding-top: 76px; }
    }

    /* Accessibility focus */
    :focus-visible { outline: none; box-shadow: var(--focus); border-radius: 8px; }

    /* Prose adjustments */
    .lead {
      color: var(--txt-1);
      font-size: 15px;
    }
    .muted { color: var(--muted); }
    hr {
      border: 0; height: 1px; background: var(--bd-soft);
      margin: 22px 0;
    }

    /* Small label row */
    .labels {
      display: flex;
      gap: 8px;
      flex-wrap: wrap;
      margin-top: 8px;
    }
  </style>
</head>
<body>
  <header class="site-header" role="banner">
    <nav class="nav" aria-label="Primary">
      <span class="dot" aria-hidden="true"></span>
      <span class="brand">N‚ÄëMethyl‚ÄëCyclazodone (NMC)</span>
      <span class="tag">Research report</span>
    </nav>
  </header>

  <main class="container" role="main">
    <h1>N‚ÄëMethyl‚ÄëCyclazodone: Pharmacological and Toxicological Assessment</h1>
    <p class="meta">
      Version 1.0 ‚Ä¢ Last updated: 2025‚Äë08‚Äë21 ‚Ä¢ Author: Tam√°s Arany ‚Ä¢ Gemini Deep Research ‚Ä¢ Contact: pharmacology@catom.dev
    </p>

    <section class="notice" aria-label="Critical safety notice">
      <h2>Critical safety notice</h2>
      <p>
        <strong>N‚ÄëMethyl‚ÄëCyclazodone (NMC)</strong> may pose a risk of severe, idiosyncratic hepatotoxicity consistent with its oxazolidinone class lineage (e.g., pemoline). Acute toxicity has included multi‚Äësystem effects in a documented case. Content is provided for research and public health awareness; it is not medical advice.
      </p>
      <div class="labels" aria-label="risk tags">
        <span class="pill warn">Hepatotoxicity risk</span>
        <span class="pill">Oxazolidinone class</span>
        <span class="pill">Idiosyncratic injury</span>
      </div>
    </section>

    <section class="card emph" aria-labelledby="exec">
      <h2 id="exec">Executive highlights</h2>
      <ul>
        <li><strong>Compound:</strong> N‚ÄëMethyl‚ÄëCyclazodone (NMC), an oxazolidinone stimulant and analogue of Cyclazodone.</li>
        <li><strong>Use context:</strong> Discussed online as a functional stimulant/nootropic; unscheduled ‚Äúresearch chemical‚Äù status in many jurisdictions.</li>
        <li><strong>Mechanism (inferred):</strong> Catecholaminergic stimulant activity involving DAT/NET reuptake inhibition and/or release; N‚Äëdemethylation to Cyclazodone observed in human case analysis.</li>
        <li><strong>Primary risk:</strong> Potential for rare but severe, unpredictable liver injury (idiosyncratic hepatotoxicity), analogous to pemoline‚Äôs risk profile.</li>
        <li><strong>Acute toxicity:</strong> Documented overdose presented with severe sympathomimetic features, neurological toxicity (choreoathetosis), ECG conduction abnormalities, rhabdomyolysis, and acute liver injury.</li>
        <li><strong>Interactions:</strong> Likely CYP‚Äëmediated metabolism; inhibitors (e.g., certain antidepressants) may elevate exposure and risk.</li>
        <li><strong>Legal context:</strong> Often unscheduled but may fall under analogue/psychoactive laws; monitored within EU EWS; UK covers under Psychoactive Substances Act.</li>
      </ul>
    </section>

    <section class="card" aria-labelledby="methods">
      <h2 id="methods">Analytical methods</h2>
      <ul>
        <li><strong>Identity:</strong> LC‚ÄëMS</li>
        <li><strong>Purity:</strong> HPLC‚ÄëUV</li>
        <li><strong>Purity caveat:</strong> ‚Äú% area by UV‚Äù differs from assay by weight; vendor claims may not reflect absolute content.</li>
      </ul>
    </section>

    <section class="card alt" aria-labelledby="identifiers">
      <h2 id="identifiers">Identifiers</h2>
      <ul>
        <li><strong>Common names:</strong> N‚ÄëMethyl‚ÄëCyclazodone, NMC</li>
        <li><strong>CAS:</strong> 14461‚Äë92‚Äë8</li>
        <li><strong>PubChem CID:</strong> 156614124</li>
        <li><strong>Class:</strong> 5‚Äëphenyl‚Äë4‚Äëoxazolidinone stimulant</li>
      </ul>
    </section>

    <section class="card" aria-labelledby="legal">
      <h2 id="legal">Legal and safety context (brief)</h2>
      <p class="lead">
        NMC is generally not explicitly scheduled in many jurisdictions but may be controlled under analogue or psychoactive‚Äësubstance laws. EU Early Warning System has recorded related notifications; the UK‚Äôs Psychoactive Substances Act broadly prohibits supply for human consumption. Availability, labeling, and compliance vary. This report does not provide legal advice.
      </p>
      <div class="labels">
        <span class="pill">EU EWS</span>
        <span class="pill">Analogue provisions</span>
        <span class="pill">PSA (UK)</span>
      </div>
    </section>

    <section class="card emph" aria-labelledby="download">
      <h2 id="download">Download the full report (PDF)</h2>
      <p>The PDF provides detailed pharmacology, toxicology, case analysis, SAR rationale, and regulatory review.</p>
      <div class="actions">
        <a class="btn primary" href="#" role="button" aria-label="Download PDF">
          <!-- You can replace with actual icon SVGs if desired -->
          ‚¨áÔ∏è Download PDF
        </a>
        <a class="btn" href="#" role="button" aria-label="View PDF in browser">
          üëÅÔ∏è View in browser
        </a>
        <span class="pill ok">Updated: 2025‚Äë08‚Äë21</span>
      </div>
    </section>

    <footer class="footer" role="contentinfo" aria-label="Document metadata">
      <div class="meta-grid">
        <div><strong>Title:</strong> N‚ÄëMethyl‚ÄëCyclazodone: A Pharmacological and Toxicological Assessment of a Novel Psychoactive Stimulant</div>
        <div><strong>Version:</strong> 1.0</div>
        <div><strong>Author:</strong> Tam√°s Arany</div>
        <div><strong>Contact:</strong> <span class="kbd">pharmacology@catom.dev</span></div>
      </div>
      <div class="muted">
        This document is provided for research and public health awareness only. It is not medical or legal advice.
      </div>
    </footer>
  </main>
</body>
</html>
